CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0030 (clinicaltrials.gov NCT No: NCT01926587)
Title:Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Azacitidine; RIGOSERTIB SODIUM (ON 01910.Na)
Study Status:Open
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of rigosertib combined with VidazaŽ (azacitidine) that
can be given to patients with MDS, AML, or CMML.

The goal of Phase II is to learn if rigosertib combined with azacitidine can
help control MDS, AML, or CMML. The safety of this drug combination will also
be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Azacitidine
RIGOSERTIB SODIUM (ON 01910.Na)
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Onconova Therapeutics Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults